B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

By Stephen L. Hauser, E. Waubant, Douglas L. Arnold, T. Vollmer, J. Antel, R. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal and 2 more. New England Journal of Medicine, 2008

1,321 citations recorded by the source corpus.

Subfields: Immunology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/a531f1e4041c84b183532de17e455f70f87d526d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Pathology and Forensic Medicine

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Cracking the BAFF code (2009, result): “and recent results from a Phase II clinical trial with rituximab (a CD20-specific B cell-depleting antibody) indicated clinical benefits from B cell-specific therapies in multiple sclerosi”
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis (2019, background): “These inflammatory sites mainly contain CD8+ T-cells, a major component of CD20+ B-cells and a variable number of plasma cells and may in their most severe manifestations become organized in structures with features of tertiary lymph follicles (green dots).”
Therapeutic antibodies for autoimmunity and inflammation (2010, background): “; rituximab and alemtuzumab (a humanized CD52-specific antibody) have shown clinical activity in Phase II clinical trials of the relapsing–remitting form of multiple sclerosi”
Multiple Sclerosis Genomic Map implicates peripheral immune cells & microglia in susceptibility (2019, background): “The enrichment is observed not only in immune cells that have long been studied in MS, such as T cells, but also in B cells, whose role has emerged more recently (25).”
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells (2012, methodology): “…studies have shown that B cell depletion therapy (BCDT) can efficiently reduce disease progression in relapsing-remitting multiple sclerosis (RR-MS) and in experimental autoimmune encephalomyelitis (EAE; Bar-Or et al., 2008; Hauser et al., 2008; Matsushita et al., 2008).”
Effector and regulatory B cells: modulators of CD4+ T cell immunity (2010, background): “The role of B cells in cellular immune responses is now receiving renewed interest owing to the emergence of clinical data showing that B cell depletion is an effective therapy for several T cell-mediated autoimmune diseases, such as multiple sclerosi”